BIOMAT Database Logo BIOMAT Database Logo

1,25-dihydroxycholesterol treatment of long-term haemodialysed patients with renal osteodystrophy. 1980

L Váry

Renal osteodystrophy still poses major problems in the management of chronic renal failure, though it had been extensively studied over the last years. The present therapeutic possibilities - massive-dose vitamin D, aluminium hydroxide and supplementary Ca-intake, administration of active vitamin D metabolites - are discussed in the light of personal observations.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D012080 Chronic Kidney Disease-Mineral and Bone Disorder Decalcification of bone or abnormal bone development due to chronic KIDNEY DISEASES, in which 1,25-DIHYDROXYVITAMIN D3 synthesis by the kidneys is impaired, leading to reduced negative feedback on PARATHYROID HORMONE. The resulting SECONDARY HYPERPARATHYROIDISM eventually leads to bone disorders. Renal Osteodystrophy,Renal Rickets,Rickets, Renal,CKD-MBD,Osteodystrophy, Renal,Chronic Kidney Disease Mineral and Bone Disorder,Osteodystrophies, Renal,Renal Osteodystrophies
D004100 Dihydroxycholecalciferols Cholecalciferols substituted with two hydroxy groups in any position. Dihydroxyvitamins D
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006887 Hydroxycholecalciferols Hydroxy analogs of vitamin D 3; (CHOLECALCIFEROL); including CALCIFEDIOL; CALCITRIOL; and 24,25-DIHYDROXYVITAMIN D 3. Hydroxyvitamins D,Hydroxycholecalciferol
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor

Related Publications

L Váry
Treatment of renal osteodystrophy with 1,25-dihydroxycholecalciferol.
March 1981, Canadian Medical Association journal,
L Váry
25-hydroxycholecalciferol in the treatment of renal osteodystrophy in haemodialysed patients.
November 1979, The International journal of artificial organs,
L Váry
Long-term effects of small doses of 1,25-dihydroxycholecalciferol in renal osteodystrophy.
March 1978, Lancet (London, England),
L Váry
Influence of long-term oral 1,25-dihydroxyvitamin D in childhood renal osteodystrophy.
January 1980, Contributions to nephrology,
L Váry
Comparison of 1,25(OH)2D3 and 24,25(OH)2D3 in the long-term treatment of renal osteodystrophy.
January 1980, Proceedings of the European Dialysis and Transplant Association. European Dialysis and Transplant Association,
L Váry
Does long-term treatment of renal anaemia with recombinant erythropoietin influence oxidative stress in haemodialysed patients?
October 1998, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
L Váry
Renal osteodystrophy in nondialysed adolescents. Long-term treatment with 1alpha-hydroxycholecalciferol.
June 1977, Archives of disease in childhood,
L Váry
Long-term 1,25-dihydroxycholecalciferol treatment in renal failure.
January 1983, Acta medica Scandinavica,
L Váry
1alpha-hydroxycholecalciferol. Long-term treatment of patients with uraemic osteodystrophy.
January 1976, Nephron,
L Váry
Long-term effects of 1,25-dihydroxy vitamin D3 and 24,25-dihydroxy vitamin D3 in renal osteodystrophy.
January 1982, The Quarterly journal of medicine,
Copied contents to your clipboard!